To further investigate the mechanism underlying tumor growth inhibition by FAP/IL-15 CAR-T cell therapy, xenograft models using HepG2-hFAP, U87, and primary hepatic carcinoma cells were established (Fig. 4A). Here, IL15 is linked to neoplasm.